534
Views
7
CrossRef citations to date
0
Altmetric
Clinical Dilema

Incorporating measurable (‘minimal’) residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia

, &
Pages 1527-1533 | Received 21 Jan 2016, Accepted 24 Feb 2016, Published online: 07 Jun 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Dao-Xing Deng, Hong-Hu Zhu, Yan-Rong Liu, Ying-Jun Chang, Guo-Rui Ruan, Jin-Song Jia, Hao Jiang, Qian Jiang, Xiao-Su Zhao & Xiao-Jun Huang. (2019) Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations. Leukemia & Lymphoma 60:9, pages 2181-2189.
Read now

Articles from other publishers (6)

Prashant Ramesh Tembhare. (2023) Monitoring Measurable/Minimal Residual Disease in Acute Myeloid Leukemia: Multiparametric Flow Cytometry-Based Approach. Indian Journal of Medical and Paediatric Oncology 44:06, pages 554-565.
Crossref
Amy Y. Wang, Lori S. Muffly & Wendy Stock. (2020) Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults. JCO Oncology Practice 16:5, pages 231-238.
Crossref
Marie Loosveld, Vanessa Nivaggioni, Isabelle Arnoux, Denis Bernot, Gérard Michel, Marie C. Béné & Marion Eveillard. (2019) Early (Day 15 Post Diagnosis) Peripheral Blood Assessment of Measurable Residual Disease in Flow Cytometry is a Strong Predictor of Outcome in Childhood B‐Lineage Lymphoblastic Leukemia. Cytometry Part B: Clinical Cytometry 96:2, pages 128-133.
Crossref
Persio Dello Sbarba & Giulia Cheloni. 2019. Leukemia Stem Cells in Hematologic Malignancies. Leukemia Stem Cells in Hematologic Malignancies 129 145 .
Peter H. Wiernik. 2018. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood 375 407 .
Kendra Sweet & Jeffrey Lancet. (2017) State of the Art Update and Next Questions: Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 17:11, pages 703-709.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.